L A VanderMolen
Overview
Explore the profile of L A VanderMolen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dillman R, Barth N, VanderMolen L, Garfield D, de Leon C, OConnor A, et al.
Cancer Biother Radiopharm
. 2001 Mar;
16(1):47-54.
PMID: 11279797
Background: We established short-term cultures of autologous tumors from patients with renal carcinoma for use as active specific immunotherapy (i.e., autologous vaccine). Methods: Between 9/91 and 9/99 the cell biology...
2.
Dillman R, Wiemann M, VanderMolen L, Bury M, Depriest C, Church C
Cancer Biother Radiopharm
. 1997 Aug;
12(4):249-55.
PMID: 10851472
Purpose: Interleukin-2 (IL-2) is an active agent for the treatment of melanoma. In animal studies, polyethylene glycol conjugated (PEG) IL-2 was found to be effective in certain IL-2-resistant models. Bolus/infusional...
3.
Gause B, Sznol M, Kopp W, Janik J, Smith 2nd J, Steis R, et al.
J Clin Oncol
. 1996 Aug;
14(8):2234-41.
PMID: 8708712
Purpose: Although high-dose interleukin-2 (IL-2) can produce durable remissions in a subset of responding patients with renal cell carcinoma (RCC), this occurs in the setting of significant toxicity. The purpose...
4.
Dillman R, VanderMolen L, Barth N, Bransford K
West J Med
. 1996 Feb;
164(2):156-61.
PMID: 8775729
Eight patient case vignettes are presented to illustrate the possible relationship between melanoma and pregnancy. We pose 10 questions regarding the risk and prognosis and answer them based on information...
5.
Dillman R, Barth N, Mahdavi K, VanderMolen L, Nayak S, OConnor A
Cancer Biother
. 1995 Jan;
10(1):25-36.
PMID: 7780484
Perhaps the best example of the integration of chemotherapy and biotherapy is autologous stem cell rescue following high dose chemotherapy. This analysis was undertaken to determine the outcome for patients...
6.
VanderMolen L, Dillman R
J Natl Cancer Inst
. 1993 Mar;
85(6):505-6.
PMID: 8445680
No abstract available.
7.
Sznol M, Clark J, Smith 2nd J, Steis R, Urba W, Rubinstein L, et al.
J Natl Cancer Inst
. 1992 Jun;
84(12):929-37.
PMID: 1629914
Background: Experiments in animal tumor models suggest that the antitumor effects of interleukin-2 (IL-2) or IL-2 in combination with lymphokine-activated killer (LAK) cells can be enhanced by chemotherapy agents such...
8.
Steis R, Urba W, VanderMolen L, Bookman M, Smith 2nd J, Clark J, et al.
J Clin Oncol
. 1990 Oct;
8(10):1618-29.
PMID: 2213099
Autologous lymphokine-activated killer (LAK) cells and recombinant human interleukin-2 (rIL-2) were administered intraperitoneally (IP) to 24 patients with malignancies limited to the peritoneal space. Ten patients had ovarian cancer, 12...
9.
Steis R, VanderMolen L, Lawrence J, Sing G, Ruscetti F, Smith 2nd J, et al.
Br J Haematol
. 1990 May;
75(1):133-5.
PMID: 2375913
No abstract available.
10.
VanderMolen L, Duffey P, Cossman J, Jaffe E, Longo D
Am J Hematol
. 1990 May;
34(1):15-20.
PMID: 2109529
The indolent follicular and diffuse lymphomas are neoplasms of B-cell origin. In several other B-cell neoplastic disorders, including multiple myeloma, hairy cell leukemia, and chronic lymphocytic leukemia, the light chain...